More than half of all Americans suffer from chronic diseases, the leading causes of death and disability. However, prompt treatment of chronic diseases can lead to better patient outcomes and a reduced burden on the healthcare system. This highlights the urgent need for electrochemical (EC) sensors that provide non‐invasive, real‐time monitoring of disease‐indicating biomarkers. Due to their high sensitivity, high selectivity, and cost‐effectiveness, EC biosensors have recently shown tremendous promise for individualized health monitoring. This review explains the working principles of EC biosensors. It summarizes the recent advances and improvements of EC biosensors for detecting biomarkers in different biofluids, including tears, saliva, breath, urine, and sweat. Through a comprehensive overview of EC biosensor technologies, this article is expected to aid the development of flexible and wearable EC biosensing systems that have the potential to provide continuous, long‐term health monitoring for both clinical and at‐home use.

Electrochemical Sensors In article 2200088, Woon‐Hong Yeo and co‐workers review flexible electrochemical sensors for the non‐invasive continuous health monitoring of analytes in biofluids.

No abstract

Seismocardiography (SCG) is the measure of local vibrations in the chest due to heartbeats. Typically, SCG signals are measured using rigid integrated circuit (IC) accelerometers and bulky electronics. However, as alternatives, recent studies of emerging flexible sensors show promise. Here, we introduce the development of wireless soft capacitive sensors that require no battery or rigid IC components for measuring SCG signals for cardiovascular health monitoring. Both the capacitive and inductive components of the circuit are patterned with laser micromachining of a polyimide-coated copper and are encapsulated with an elastomer. The wearable soft sensor can detect small strain changes on the skin, which is wirelessly measured by examining the power reflected from the antenna at a stimulating frequency. The performance of the device is verified by comparing the fiducial points to SCG measured by a commercial accelerometer and electromyograms from a commercial electrode. Overall, the human subject study demonstrates that the fiducial points are consistent with data from commercial devices, showing the potential of the ultrathin soft sensors for ambulatory cardiovascular monitoring without bulky electronics and rigid components.